Key Highlights

  • Faron Pharmaceuticals Oy (LSE:FARN) rose 1.71% on the AIM market of the London Stock Exchange on 20 October 2026.
  • The randomised Phase 2b BEXERA trial of bexmarilimab in treatment-naive high-risk MDS was scheduled to begin enrolment in October 2026.
  • Faron hosted an R&D Day on 8 October 2026 covering MDS data, the pipeline, sarcoma expansion and market opportunity.
  • Matured BEXMAB data presented at EHA 2026 confirmed durable efficacy and bone marrow reprogramming.
  • A EUR 40.1 million rights issue completed in April 2026 funds the next stage of development.

Why Faron (LSE:FARN) Is in Focus Today

Faron Pharmaceuticals, the Finnish clinical-stage biopharmaceutical company dual-listed on AIM and Nasdaq First North, gained 1.71% on the AIM market on 20 October 2026. The move comes during a month that Faron had long flagged as pivotal, with its randomised Phase 2b BEXERA trial due to start enrolling patients in October 2026.

LSE:FARN has also remained in the spotlight following its R&D Day on 8 October, when management and external experts set out the case for bexmarilimab across blood cancers and solid tumours. Biotech investors often reposition after such events as they digest the data and timelines presented.

Bexmarilimab: Targeting Clever-1

Bexmarilimab is Faron's wholly owned investigational immunotherapy. It targets Clever-1, a receptor on immunosuppressive macrophages, with the aim of reprogramming the tumour microenvironment and triggering a stronger anti-tumour immune response. The approach is designed to overcome resistance to existing therapies, an important unmet need in blood cancers such as myelodysplastic syndromes, or MDS.

The US Food and Drug Administration has granted bexmarilimab Fast Track Designation in MDS in combination with azacitidine and Orphan Drug Designation in MDS, both valuable regulatory advantages.

BEXMAB Data and the Road to BEXERA

The Phase 1/2 BEXMAB study evaluated bexmarilimab with azacitidine in MDS patients. In June 2026, Faron presented matured data at the European Hematology Association congress, which it said confirmed durable efficacy and bone marrow reprogramming in higher-risk MDS.

Building on these results, Faron announced in April 2026 that the randomised Phase 2b BEXERA trial would evaluate two doses of bexmarilimab combined with azacitidine against placebo plus azacitidine in treatment-naive high-risk MDS. Faron selected Parexel to support the trial. A randomised, placebo-controlled design is important because it can generate the robust evidence regulators and potential partners require.

R&D Day Highlights

The 8 October R&D Day featured chief scientific officer Maija Hollmén presenting the MDS data, chief medical officer Petri Bono reviewing the pipeline and Dr César Serrano of the Vall d'Hebron Institute of Oncology discussing BEXAR, the plan to expand bexmarilimab into sarcomas. Chief business officer Ralph Hughes outlined the commercial opportunity. The event aimed to show that bexmarilimab has potential well beyond a single indication, which matters for future partnering discussions.

Faron is also working with City of Hope on an investigator-initiated Phase 2 trial in relapsed or refractory MDS, extending the clinical footprint at limited cost.

Funding Position

Faron completed a EUR 40.1 million rights issue in April 2026, with participation from the Leukemia and Lymphoma Society's Therapy Acceleration Program, which has backed the bexmarilimab programme since 2022. The proceeds are intended to fund BEXERA and related activities. Funding has historically been a key concern for investors in LSE:FARN, so the rights issue reduces near-term financing risk, though future capital needs remain.

Why MDS Matters

Higher-risk MDS is a serious blood cancer with limited treatment options, and many patients do not respond durably to standard hypomethylating agents such as azacitidine. A therapy that improves response rates and duration could address a significant unmet medical need and command a valuable market. This is why large pharmaceutical companies watch MDS data closely and why Faron's progress attracts international attention.

Risks Investors Are Weighing

Clinical development carries high risk. Phase 2b results may not replicate earlier findings, and enrolment timelines can slip. Faron remains loss-making and will likely need further funding or a partnership before any approval. Competition in MDS is intensifying, and share price volatility is common around data readouts and financing events.

What Investors Are Watching Next

Investors in Faron Pharmaceuticals will track confirmation that the first patients have been enrolled in BEXERA, the pace of site activation, progress on the City of Hope trial and any partnering discussions. Further detail on the sarcoma programme and the company's cash runway will also be important. Faron reports half-yearly, so the full-year 2026 report in early 2027 will be the next scheduled financial update. Any business development news would be a major catalyst for LSE:FARN.